REGN vs TPCS · P/E 14, rev $14.34B vs rev $34.0M
Regeneron Pharmaceuticals Inc (REGN) versus TechPrecision Corporation Common stock (TPCS) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
TechPrecision Corporation Common stock (TPCS) is a metal fabrication company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported TPCS revenue for 2025-03-31 was $34.0M. Net income was -$2.7M. Revenue was up 7.7% from 2024-03-31 to 2025-03-31. TPCS currently screens at market cap $34.5M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TPCS currently screens at market cap $34.5M.
Not investment advice. Open the REGN and TPCS stock pages for the full models.
Not investment advice.